marijuana stocks

OrganiGram Holdings Inc. (OGRMF)

 

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Nov 30, 2014 Jul 31, 2014 Apr 30, 2014 Jan 31, 2014
Total Revenue 12   –   –   –  
Cost of Revenue 6
Gross Profit 6   –   –   –  
Operating Expenses
Research Development
Selling General and Administrative 723 177 24 12
Non Recurring 2 (11)
Others
Total Operating Expenses
Operating Income or Loss (718) (177) (26) (2)
Income from Continuing Operations
Total Other Income/Expenses Net 5
Earnings Before Interest And Taxes (718) (172) (25) (2)
Interest Expense
Income Before Tax (718) (172) (25) (2)
Income Tax Expense
Minority Interest
Net Income From Continuing Ops (718) (172) (25) (2)
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (718) (172) (25) (2)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (718) (172) (25) (2)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

TerrAscend Corp. (TRSSF) to Acquire Gage Cannabis

TerrAscend to Acquire Gage Cannabis TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE:…

Cara Therapeutics, Inc. (CARA) Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase…

$PMCB Melligen Cells Prove Safe in First Preclinical Test

PharmaCyte Biotech’s Melligen Cells Prove Safe in First Preclinical Test  PharmaCyte Biotech,…

 Tetra Bio-Pharma (TBPMF) Discusses the Potential of Their ARDS-003 Drug in the Fight Against COVID-19

Tetra Bio-Pharma Discusses the Potential of Their ARDS-003 Drug in the Fight…